Eisai and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) had entered a research collaboration aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glia cells.
DZNE is a major interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases.
The collaboration will incorporate DZNE’s expertise in the fundamental and clinical research with Eisai’s abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.
Prof. Pierluigi Nicotera, Chairman of the DZNE’s Executive Board, said: “We are pleased to have formed this collaboration with Eisai, which has an outstanding track record and a company-wide commitment to providing innovative treatments in the neurodegenerative disorders field.
“We think that this collaboration will be able to accelerate creation of new treatments for neurodegenerative disorders, including those for Alzheimer’s and Parkinson’s.
“The DZNE will contribute knowledge and technical expertise in studying disease processes combined with our translational, patient-oriented approach that involves close interaction between fundamental and clinical research.”